ChemicalBook > Product Catalog >Biochemical Engineering >Biochemical Reagents >Agonist Inhibitors >N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide

N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide

Request For Quotation
N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide Suppliers list
Company Name: Shanghai Boyle Chemical Co., Ltd.  
Tel:
Email: sales@boylechem.com
Company Name: ChemShuttle, Inc.  
Tel: 0510-83588313-811 18800520310
Email: sales@chemshuttle.com
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Company Name: AdooQ BioScience, LLC   
Tel: +1 (866) 930-6790
Email: info@adooq.com
Company Name: CEG Chemical Science&Technology Co., Ltd.  
Tel: Mobile:13665161512
Email:

N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide manufacturers

  • LY-404187
  • LY-404187 pictures
  • $48.00
  • 2026-04-22
  • CAS:211311-95-4
  • Purity: 99.34%
  • Supply Ability: 10g
N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide Basic information
Product Name:N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide
Synonyms:LY404187;N-(2-(4'-Cyano-[1,1'-biphenyl]-4-yl)propyl)propane-2-sulfonaMide;N-[2-(4'-Cyano[1,1'-biphenyl]-4-yl)propyl]-2-propanesulfonamide;N-2-(4-(4-Cyanophenyl)phenyl)propyl-2-propanesulfonamide;CS-2739;100775;LY-404187; LY 404187;LY-404187 N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide
CAS:211311-95-4
MF:C19H22N2O2S
MW:342.46
EINECS:
Product Categories:
Mol File:211311-95-4.mol
N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide Structure
N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide Chemical Properties
Boiling point 519.0±60.0 °C(Predicted)
density 1.19±0.1 g/cm3(Predicted)
storage temp. Sealed in dry,Room Temperature
solubility DMF: 15mg/mL; DMSO: 15mg/mL; DMSO:PBS (pH 7.2) (1:4): 0.2mg/mL; Ethanol: 3mg/mL
form A solid
pka11.24±0.40(Predicted)
color White to off-white
Safety Information
MSDS Information
N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide Usage And Synthesis
DescriptionLY404187 is a benzothiadiazide positive allosteric modulator of AMPA receptors. It increases glutamate-induced activation of GluR1i, -2i, -2o, -3i, and -4i subunit-containing AMPA receptors with EC50 values of 5.65, 0.15, 1.44, 1.66, and 0.21 μM, respectively, in a calcium influx assay. LY404187 is selective for these AMPA receptors over GluR6 subunit-containing kainate receptors at 10 μM. LY404187 increases currents induced by glutamate and AMPA in rat prefrontal cortex pyramidal neurons (EC50s = 1.3 and 1.2 μM, respectively) but not in AMPA-stimulated primary rat embryonic hippocampal or primary cerebellar Purkinje neurons. LY404187 prevents decreases in the number of dopaminergic neurons in the substantia nigra induced by MPTP and 6-OHDA in mouse and rat, respectively, models of Parkinson’s disease when administered at a dose of 0.5 mg/kg per day.
UsesLY 404187 is a novel positive allosteric modulator of AMPA receptors.
in vivo

LY-404187 (0.5 mg/kg; s.c for 11 days) can prevent MPTP-induced neurotoxicity in mice[4].
LY-404187 (0.5 mg/kg; s.c. for 28 days) attenuates apomorphine-induced contraversive rotations and affords significant protection against the loss of tyrosine hydroxylase positive nigral cell bodies[4].
LY-404187 (0.1 or 0.5 mg/kg; s.c. for 14 days) affords functional, neurochemical and histological protection after infusion of 6-hydroxydopamine into the substantia nigra in rats[4].
LY-404187 (0.5 mg/kg; s.c. for 14 days) delayed treatment provides functional and histological improvement, suggesting a trophic action as administration is initiated after cell death[4].
LY-404187 (0.1 and 0.5 mg/kg; s.c. for 14 days) increases GAP-43 immunoreactivity in the striatum in a dose-dependent manner[4].

Animal Model:Male C57BL/6J mice (20-25 g) are challenged with MPTP on day 8[4]
Dosage:0.5 mg/kg
Administration:S.c; twice daily on weekdays and once daily at weekends for 11 days
Result:Attenuated the loss of tyrosine hydroxylase immunoreactivity in the substantia nigra.
No significant change in tyrosine hydroxylase immunoreactivity in the dorsal and ventral striatum.
storageStore at +4°C
References[1] P MIU . Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro[J]. Neuropharmacology, 2001, 40 8: Pages 976-983. DOI: 10.1016/s0028-3908(01)00027-2
[2] De Souza, F.I., Zumiotti, A.V., and Da Silva, C.F. Neuregulins 1-α and 1-β on the regeneration the peripheral nerves[J]. Acta Ortop Bras.
[3] M GATES  D B  A Ogden. Pharmacological effects of AMPA receptor potentiators LY392098 and LY404187 on rat neuronal AMPA receptors in vitro[J]. Neuropharmacology, 2001, 40 8: Pages 984-991. DOI: 10.1016/s0028-3908(01)00040-5
[4] MICHAEL J O’NEILL . Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson’s disease[J]. European journal of pharmacology, 2004, 486 2: Pages 163-174. DOI: 10.1016/j.ejphar.2003.12.023
N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide Preparation Products And Raw materials
Tag:N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide(211311-95-4) Related Product Information
Ruetasolv BP 4103 - mixture of isomeres isopropylbiphenyls. for further details please inquire at marketing contacts. speciality chemicals 2-[[(2E)-3-(2-Naphthalenyl)-1-oxo-2-buten-1-yl]amino]benzoic acid Ritlecitinib 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide Upadacitinib Q-VD-OPh hydrate H3B-6527 Senexin B 2-(2-((4-bromophenyl)amino)-2-oxoethoxy)-N-(2-(methyl(phenyl)amino)-2-oxoethyl)benzamide (S)-4-(4-((2-(3,5-diMethylphenyl)pyrrolidin-1-yl)Methyl)phenoxy)-3-fluorobenzaMide BMS-986205 Budiodarone tartrate COH-29